AMARILLO, Texas, June 11 /PRNewswire-FirstCall/ -- Amarillo Biosciences, Inc. (OTC Bulletin Board: AMAR) announces supply agreements with STC International (East Brunswick, New Jersey) for the territories of China and Taiwan and with Majsons Corporation (Karachi) for the territory of Pakistan.
Maxisal(TM), a patented dietary supplement, is the trade name for pharmaceutical grade anhydrous crystalline maltose, which has been found to relieve complaints of dry mouth, enhance salivary function, and promote oral comfort. Amarillo Biosciences, Inc. is the exclusive worldwide (outside Japan) supplier of Maxisal(TM) for the dry mouth market.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc. said, "We are very pleased that Maxisal(TM) will be sold by our new distributors in their respective territories. Researchers estimate that at least 20% of the population over 50 years of age suffer from persistent complaints of dry mouth. The number of people with dry mouth is even greater if you include people who suffer from autoimmune diseases or take one of the many prescription medications that cause dry mouth."
Dr. Cummins concluded, "Our innovative, new product will enable us to continue to take advantage of the many growth opportunities in the biotechnology market. We believe this dry mouth market is poised for significant growth."
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a pioneer in the research of low-dose orally administered interferon alpha as a treatment for a variety of conditions including Sjogren's syndrome, fibromyalgia syndrome, Behcet's disease, hepatitis B and C, and opportunistic infections in patients who are HIV positive. Additional information is available on the Amarillo Biosciences, Inc. web site at http://www.amarbio.com .
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon alpha or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2001.